Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria.
about
Antimalarial drug resistanceArtemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malariaAssessment of the pharmacodynamic properties of antimalarial drugs in vivoSevere falciparum malaria. World Health Organization, Communicable Diseases ClusterMefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy numberAssessment of copy number variation in genes related to drug resistance in Plasmodium vivax and Plasmodium falciparum isolates from the Brazilian Amazon and a systematic review of the literatureRandomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria.Artemisinin-based combination therapy in pregnant women in Zambia: efficacy, safety and risk of recurrent malariaFactors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children.Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria.Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data.Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria.Emerging artemisinin resistance in the border areas of Thailand.Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics.In vivo parasitological measures of artemisinin susceptibilityPsychosis with paranoid delusions after a therapeutic dose of mefloquine: a case reportFactors contributing to anemia after uncomplicated falciparum malaria.Coartemether (artemether and lumefantrine): an oral antimalarial drug.World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in childrenAntimalarial drug therapy: the role of parasite biology and drug resistance.Investigation of the in vitro gender-specific partitioning of mefloquine in malarial infected red blood cells and plasmaThe neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria.Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistanceThe prevalence and degree of resistance of Plasmodium falciparum to first-line antimalarial drugs: an in vitro study from a malaria endemic region in Yemen.Malaria parasites giving rise to recrudescence in vitro.Antimalarial drugs clear resistant parasites from partially immune hosts.Predictors of the failure of treatment with chloroquine in children with acute, uncomplicated, Plasmodium falciparum malaria, in an area with high and increasing incidences of chloroquine resistance.In vitro sensitivity of Plasmodium falciparum and clinical response to lumefantrine (benflumetol) and artemether.An open label randomized comparison of mefloquine-artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand.Efficacies of mefloquine alone and of artesunate followed by mefloquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan.Mefloquine in infants and young children.Pharmacokinetics of mefloquine administered with artesunate in patients with uncomplicated falciparum malaria from the Brazilian Amazon basinWhich drug is effective and safe for acute malaria in pregnancy? Reviewing the evidence
P2860
Q22061790-FC463B8D-7CD8-4093-A89A-A6D8AD1AD30BQ24246332-291EA247-BE42-4476-A585-233A1C932175Q24670346-86D37F23-1BDB-4888-92DF-8AD4F07B9B5FQ29614923-FBE64A8A-45AB-4062-9BC8-1165295FBBDDQ29615128-A73B303F-C842-44A6-AE79-0EE6FFD115AAQ33577218-EA7AB4AA-CD93-4D6D-B54B-1A72FBBF462EQ33690621-DBC0F12C-4CBA-44C5-A392-F1E0C14AF777Q33696767-3B797840-9F3A-45EE-8AA2-87F1020A6032Q33711891-2E0FC116-AB7A-4FF7-BB19-F12364163316Q33976068-9883B74E-2A9B-46DD-BD9A-02CFCFFC914BQ34043921-5CB7604E-37B4-41A3-BDAB-E977FAE97898Q34160147-F801C1C1-D5CD-4A1F-9611-EAA3DF8EEF7BQ34343530-715EB299-B23A-4F55-B100-A993C056A8A5Q34699136-45A6E6D7-67BA-427E-B908-A3DFC0F2FAEAQ34921155-5B077381-B5BC-4421-A012-57ACBB2C7823Q35024655-65291E90-A1AC-4B7C-93B3-CF4C6B796372Q35112361-27380727-D154-418C-B7BD-09A15274402DQ35917361-1A98A5E6-3E44-470E-9C7C-3FBBF234D011Q36054710-CF708107-A957-4E16-AF7B-5459C4FD71E0Q36593867-DA786476-F43E-46ED-BA8A-CFE2ED9346BDQ36652599-09D47127-B15D-48C6-87E5-5AA7FE26C1BDQ37225808-0EA0462C-D293-4B70-9FED-A1C28EEFCA0CQ37346189-DCF08076-1BD8-472D-A05D-4FB2CCB971E1Q37444728-2D47BF38-B418-4DB4-B41B-A940AFAF368CQ39195148-692F57B1-151C-41F9-A2FB-EEA7A2259F60Q39292635-FBCECC27-AF41-4D89-ABDF-3A2B87CA9E72Q39478595-D40E67EA-6C53-4AB2-9D11-89F5E71A31B9Q40498935-F0EF0F36-0235-4658-9085-0E538A0CE437Q41611009-D98689E3-8634-48BF-B191-FFD874AD94E1Q43601958-4356F3E7-86A7-4867-8442-CF45463D3049Q46425189-C4702CD7-249F-46BB-B7BF-89D164F08F13Q48035075-137D48AF-52C6-48EF-A8DE-F25740C6F70CQ56363318-F5EB79DA-927F-40E5-88B8-BE911ACCD758Q57013833-4195D567-2BFD-45EA-A9A9-D37DB5F7E9E0
P2860
Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Predictors of mefloquine treat ...... omplicated falciparum malaria.
@en
type
label
Predictors of mefloquine treat ...... omplicated falciparum malaria.
@en
prefLabel
Predictors of mefloquine treat ...... omplicated falciparum malaria.
@en
P2093
P50
P1476
Predictors of mefloquine treat ...... omplicated falciparum malaria.
@en
P2093
Chongsuphajaisiddhi T
Luxemburger C
P304
P356
10.1016/0035-9203(95)90435-2
P577
1995-11-01T00:00:00Z